Hepatitis The hepatitis C virus is the major cause of progressive
liver diseases and a public health problem worldwide. At
present, hepatitis C has become a curable disease with the
use of new interferon-free regimens based on direct-Acting
Antiviral agents (DAA.s). Direct-acting antivirals directly target
the viral protease, polymerase, or non-structural proteins. These
agents have been approved by FDA in various combinations to
interrupt HCV replication at different sites. The introduction of
DAAs has increased the number of patients who respond to
treatment, and has changed radically the treatment of chronic
HCV with reported sustained virologic response (SVR) rates
exceeding 95% in treating patients. Treatment for chronic HCV
is based on guidelines from the Infectious Diseases Society
of America (IDSA) and the American Associations for the Study
of Liver Diseases (AASLD), in collaboration with the International
Antiviral Society-USA (IAS-USA). Based on available
resources, patients at high risk for liver-related complications
and severe extrahepatic hepatitis C complications should be
given high priority for treatment. This article aims to summarize
newly available treatment regimens and special considerations
for each regimen, such as coinfection with human immunodeficiency
virus (HIV), compensated or decompensated cirrhosis,
and Post-transplant patients.